Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)
Tango Therapeutics' (TNGX) quarterly Non Operating Investment Income came in at -$443000.0 in Q1 2024, down 129.45% year-on-year from $1.5 million in Q2 2023, and down 151.1% quarter-over-quarter from $867000.0 in Q4 2023.
Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024) Analysis & Trends
Tango Therapeutics' Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$443000.0 for Q1 2024.
- On a quarterly basis, Non Operating Investment Income fell 129.45% year-over-year to -$443000.0 in Q1 2024; TTM through Mar 2024 was $1.9 million, a 60.79% increase from a year earlier, with the FY2025 full-year figure at -$112000.0, down 174.67% from the prior year.
- Non Operating Investment Income declined to -$443000.0 in Q1 2024 per TNGX's latest filing, from $867000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.5 million in Q1 2023 and bottomed at -$2.6 million in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$9000.0 (2020), against an average of -$17866.7.
- Across the five-year window, Non Operating Investment Income slumped 17733.33% in 2022 and jumped 264.24% in 2023, its largest moves.
- Year by year, Non Operating Investment Income stood at -$9000.0 in 2020, then slumped by 8288.89% to -$755000.0 in 2021, then jumped by 252.45% to $1.2 million in 2022, then dropped by 24.67% to $867000.0 in 2023, then tumbled by 151.1% to -$443000.0 in 2024.
- Per Business Quant, the three latest TNGX Non Operating Investment Income figures stand at -$443000.0 (Q1 2024), $867000.0 (Q4 2023), and $836000.0 (Q3 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Tango Therapeutics | 3.82 Bn | 3.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -443,000.00 |
| Mar 31, 2024 | -443,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | -509,000.00 |
| Sep 30, 2022 | -509,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Mar 31, 2022 | -2.65 Mn |
| Mar 31, 2022 | -2.65 Mn |
| Dec 31, 2021 | -755,000.00 |
| Dec 31, 2021 | -755,000.00 |